SecBot SecBot
15-12G ·Filed Jun 22, 2026

KALV

KalVista Pharmaceuticals, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed4mo ago SEC0001140361-26-025858
Deregistration
Actionable Insight ▼ Bearish

With only one holder of record and SEC reporting suspended, the stock will likely be delisted from Nasdaq and move to the OTC markets with minimal liquidity. Existing shareholders should expect no further public disclosures. Monitor for any subsequent going-private transaction filings or a potential squeeze-out of minority holders.

DirectionBearish
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

Executive Summary

KalVista Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective June 22, 2026. The filing states there is only one holder of record, indicating the company has gone private or been acquired, and will cease all SEC reporting obligations. This is a significant event that eliminates public transparency and liquidity for any remaining public shareholders.

Key Facts

  • Filed Form 15-12G to terminate registration under Section 12(g) of the Securities Exchange Act of 1934
  • Effective date: June 22, 2026
  • Approximate number of holders of record as of certification date: One holder
  • Company will suspend duty to file reports under Sections 13 and 15(d)
  • Signed by John Hess, Chairman of the Board, President, and General Manager
  • Formerly known as Carbylan Therapeutics, Inc. (name change in 2014)

Financial Impact

No financial figures provided in filing; the company is deregistering with only one holder of record, implying a going-private transaction or acquisition has occurred.

liquiditytransparencyshareholder rights

Risk Factors

  • Complete loss of public market liquidity and price discovery
  • No ongoing SEC reporting means no financial transparency for remaining shareholders
  • Potential for a below-market squeeze-out or freeze-out merger at an unfavorable price
  • Delisting from Nasdaq likely, moving to OTC Pink Sheets with limited trading

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
54% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
15-12G Filing (Primary)0001140361-26-025858
Document: 0001140361-26-025858-index-headers.html0001140361-26-025858
Document: 0001140361-26-025858-index.html0001140361-26-025858
Document: 0001140361-26-025858.txt0001140361-26-025858

Track record

12 reports on KALV

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +4.15% at T+5 after the Apr 17, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Jun 22, 202621w ago 15-12G Bearish 7/10 Viewing No price data
  2. Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
  3. Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
  4. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
  5. May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
  6. May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
  7. Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
  8. Apr 17, 202630w ago Insider Cluster Bearish 6/10 Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
  9. Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
  10. Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 5h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026